For a comprehensive view of trading tips and analyst research reports that are authoritative, professional, timely, and thorough, helping you uncover potential thematic opportunities.

Trading Suspensions

Lakala (300773), Xinya Process (002388, rights protection), Rongfeng Holdings (000668), and Beibu Gulf Port (000582) are suspended from trading.

Trading Resumptions

None.

Major Corporate Events

Rongfeng Holdings: The controlling shareholder is planning a change in control, and the stock will be suspended from trading starting October 8. The company announced that its controlling shareholder, Shengshida Investment Co., Ltd., is planning a change in control of the company, which may result in a change of the controlling shareholder and actual controller. The company's stock will be suspended from the opening of trading on October 8, with an expected suspension of no more than 2 trading days.

Beibu Gulf Port: Plans to acquire 100% equity of Henggang Terminal, with the stock suspended from trading on October 8. The company announced that it is planning to acquire 100% equity of Guangxi Free Trade Zone Qinzhou Port Area Henggang Terminal Co., Ltd. from Guangxi Beibu Gulf International Port Group Co., Ltd. and Qinzhou Port Construction Investment Co., Ltd. through the issuance of shares and cash payments, and to raise supporting funds. The company's stock will be suspended from the opening of trading on October 8 (Thursday).

Xinya Process: Planning to acquire a controlling stake in Qiyuan Gas, with the stock suspended from trading starting October 8. The company announced that it is planning to acquire a controlling stake in Shanghai Qiyuan Gas Development Co., Ltd. ("Qiyuan Gas") through the issuance of shares and cash payments, and to raise supporting funds. This transaction is expected to constitute a major asset restructuring. The company's securities will be suspended from the opening of trading on October 8, and the transaction plan is expected to be disclosed within no more than 10 trading days.

Sanan Optoelectronics: Vice Chairman and General Manager Lin Kechuang has been released from detention and can perform his duties normally. The company announced that it previously disclosed on April 9, 2026, that Vice Chairman and General Manager Lin Kechuang was placed under detention and investigated by a supervisory agency. On October 5, 2026, the company received a "Notice of Release from Detention" issued by the supervisory agency, and the supervisory agency has lifted the detention measures against Mr. Lin Kechuang. Currently, Mr. Lin Kechuang can perform his duties normally, and the company's production and operations are normal.

Garden Bio: Signed a project cooperation agreement with the Guangzhou National Laboratory. The company announced that it recently signed a "25-Hydroxycholesterol New Drug R&D Project Cooperation Agreement" with the Guangzhou National Laboratory to jointly promote the R&D, registration, production, and commercialization of 25-hydroxycholesterol and its prodrug broad-spectrum antiviral drugs through the establishment of a joint venture. The joint venture will be led by the company for subsequent operations, with the company holding no less than 51%.

Yahong Medicine: Signed an exclusive licensing agreement with Theramex. The company announced that it recently signed a conditional exclusive licensing agreement with Theramex. According to the agreement, Theramex will obtain exclusive rights to APL-1702 (trade name: Xiwelta®/CEVIRA®) in European countries, as well as Australia, New Zealand, and Turkey. The company retains the relevant rights in the rest of the world. In this transaction, Yahong Medicine will receive a $15 million upfront payment, an $11 million near-term registration milestone payment, as well as commercialization milestone payments and tiered sales royalties. The total transaction amount exceeds $250 million.

Allist: The Phase III clinical trial of furmonertinib did not reach the primary endpoint. The company announced that the FURVENT Phase III trial of its product, furmonertinib mesylate tablets ("furmonertinib"), as a monotherapy for previously untreated patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, did not reach the primary endpoint, namely progression-free survival (PFS) assessed by blinded independent central review (BICR). The company, together with ArriVent, is evaluating the complete FURVENT dataset to determine the next steps. As of September 30, 2026, the company had invested approximately RMB 70.82 million in the pivotal clinical trial of furmonertinib for first-line treatment of exon 20 insertion mutations. The above R&D expenses have been recognized in profit or loss for the corresponding accounting periods when incurred and will not have a material impact on the company's current performance.

Betta Pharmaceuticals: BPI-572270 capsules received FDA approval for a new drug clinical trial. The company announced that the clinical trial application for BPI-572270 capsules filed by its wholly-owned subsidiary, Jingyao Biotechnology, has been approved by the U.S. FDA. The drug is intended for advanced solid tumors.

Foshan Lighting: The Fenjiang North Road Central District plot is listed for transfer, and the company is expected to receive compensation income of approximately RMB 550 million. The company released an announcement on the progress of asset disposal and public land listing and transfer. Recently, the company handed over the Fenjiang North Road Central District plot to the Chancheng District Land Reserve Center of Foshan City, and the Chancheng Branch of the Foshan Natural Resources Bureau publicly listed and transferred the Central District plot on September 30 at the Chancheng Branch of the Foshan Public Resources Trading Center. If all or part of the land transfer is successful, the company will receive land reserve compensation payments according to the agreed conditions. The company's booked reserve of the Fenjiang North Road Central District plot is mainly to revitalize the company's assets, improve the return on assets, and provide financial support for the future development of the company's main business. If the transfer is completed in full at a price of RMB 6,700 per square meter, the company expects to receive booked reserve compensation income of approximately RMB 550 million for the Central District plot, and after deducting relevant costs, expenses, and taxes before reserve, the expected net income is approximately RMB 340 million. This transaction is still subject to uncertainty.

Performance Outlook

Huahai Pharmaceutical: Expected net profit for the first three quarters of 2026 to increase by approximately 170% to 190% year-on-year. The company announced that it expects net profit attributable to shareholders of the listed company for the first three quarters of 2026 to be RMB 1.028 billion to RMB 1.103 billion, an increase of approximately 170% to 190% year-on-year, compared with RMB 380 million in the same period of 2025; non-GAAP net profit is expected to be RMB 662 million to RMB 743 million, an increase of approximately 145% to 175% year-on-year, compared with RMB 270 million in the same period of 2025. The performance growth was mainly affected by growth in API, domestic formulation, and U.S. formulation businesses, arbitration-related income, gains from the disposal of subsidiary equity, and a decrease in R&D expenses.

Feilong Shares: Net profit for the first three quarters is expected to decrease by 59.2% to 66.87% year-on-year. The company disclosed its performance forecast, expecting attributable net profit for the first three quarters of 2026 to be RMB 95 million to RMB 117 million, a year-on-year decrease of 59.2% to 66.87%; basic earnings per share of RMB 0.17 to RMB 0.2. During the reporting period, due to the combined impact of multiple phased factors such as intensified competition in the automotive industry, rising raw material prices, exchange rate fluctuations, and new businesses still in the cultivation stage, the company's net profit decreased year-on-year.

Share Buybacks

Allist: The actual controller proposed a share buyback of RMB 100 million to RMB 200 million. The company announced that its actual controller, chairman, and general manager Du Jinhao proposed that the company repurchase shares with its own funds, with a total repurchase amount of RMB 100 million to RMB 200 million (inclusive). The repurchased shares will all be used for employee stock ownership plans or equity incentives at an appropriate time in the future.

Increases and Decreases in Holdings

Wuzhou Communications (rights protection): The controlling shareholder plans to increase its holdings in the company by RMB 89.045 million to RMB 178 million. The company announced that its controlling shareholder, Jiaotou Group, plans to increase its holdings of the company's shares within 12 months through centralized bidding transactions on the Shanghai Stock Exchange and other methods, with a planned increase amount of no less than RMB 89.045 million and no more than RMB 178 million.

Shandong Road and Bridge: The controlling shareholder and its concert parties increased their holdings, touching an integer multiple of 1%. The company announced that it recently received a notice from Expressway Investment Holding, which increased its holdings of the company's shares by 1.7073 million shares through centralized bidding transactions on September 30, accounting for 0.11% of the company's total share capital. After this increase, the controlling shareholder and its concert party Expressway Investment Holding together hold 870.769 million shares of the company, and their shareholding ratio increased from 55.98% to 56.09%, with the shareholding change touching an integer multiple of 1%.

Guanghua Technology (rights protection): The controlling shareholder plans to reduce its holdings in the company by no more than 3%. The company announced that its controlling shareholder and actual controller Zheng Chuangfa plans to reduce its holdings of the company's shares by no more than 14.0581 million shares (no more than 3% of the company's total share capital) through centralized bidding and block trades.

Zhongya Shares: The actual controller and its concert parties plan to collectively reduce their holdings by no more than 11.779 million shares. The company announced that chairman and actual controller Shi Zhongwei plans to reduce his holdings by no more than 9 million shares; shareholder Hangzhou Fupai Management Consulting Co., Ltd. plans to reduce its holdings by no more than 1.5 million shares; shareholder Hangzhou Gaodi Enterprise Management Consulting Co., Ltd. plans to reduce its holdings by no more than 600,000 shares; shareholder Song Lei plans to reduce her holdings by no more than 600,000 shares; and shareholder Xu Juhua plans to reduce her holdings by no more than 79,000 shares. Hangzhou Fupai, Hangzhou Gaodi, Song Lei, and Xu Juhua are concert parties of Shi Zhongwei. The above reduction entities collectively plan to reduce their holdings by no more than 11.779 million shares.

Major Contracts

Roman Shares: A subsidiary signed a RMB 277 million computing power equipment procurement contract. The company announced that its controlling subsidiary, Shanghai Wutongshu High-Tech Co., Ltd., signed a "Computing Power Equipment Procurement Framework Contract" with Beijing Guangma Software Co., Ltd., with a contract amount of approximately RMB 277 million. Wutong High-Tech will procure computing power equipment for Beijing Guangma Software and provide related technical services. This transaction is a daily operating business of the subsidiary, and the impact on the company's current performance in 2026 remains uncertain.

Honglu Steel Structure: Wholly-owned subsidiaries collectively won bids for engineering projects totaling RMB 278 million. The company announced that its wholly-owned subsidiary, Guoyang County Honglu Building Materials Co., Ltd., received a "Notice of Award" issued by Zhongcheng Guoshi (Anhui) Supply Chain Management Co., Ltd., confirming the company as the winning bidder for the "*** Data Center" project and the "*** Annual Production of 100,000 Tons of High-Performance Lithium-Ion Battery Anode Material Project." The total winning bid quantity (bill of quantities) for the above projects is approximately 52,800 tons, with a total winning bid amount of approximately RMB 278 million, accounting for 1.26% of the company's total operating revenue in 2025.

Weihai Shares: Pre-won the bid for an engineering project worth approximately RMB 162 million. The company announced that it is the winning candidate for the "Tiaoxi Flood Control and Management Project Construction Section 2" project, with a bid price of approximately RMB 162 million.